Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best falling ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk's anti-TFPI antibody concizumab has ... including Japan, Australia, and Switzerland, but was rejected by the FDA last year with a request for more information related to the ...

US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...

Investing.com - European stock markets edged higher Friday, continuing the positive tone seen on Wall Street, with investors digesting more corporate earnings as well as the latest economic activity ...